CJC-1295 Complete Drug-Drug Interaction Profile

How CJC-1295 Works: The Mechanism Behind Its Interactions

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified version of GRF 1-29 with four amino acid substitutions that resist dipeptidyl peptidase IV (DPP-IV) cleavage. The Drug Affinity Complex (DAC) variant adds a maleimidopropionic acid linker that binds albumin in vivo, extending the peptide's half-life from roughly 30 minutes to approximately 5.8 to 8 days 1.

This prolonged action is the source of most interaction concerns. In the Teichman et al. Single-dose escalation study (N=33), a single subcutaneous injection of CJC-1295 DAC at 60 or 90 mcg/kg raised mean IGF-1 levels by 1.5- to 3-fold above baseline and sustained that elevation for 6 to 14 days 1. That extended pharmacodynamic window means any drug whose efficacy or toxicity is modulated by GH or IGF-1 levels faces a prolonged period of altered response, not just a brief spike.

Unlike small-molecule drugs metabolized through cytochrome P450 enzymes, CJC-1295 is a peptide cleared by proteolysis and renal filtration. It does not inhibit or induce CYP1A2, CYP2D6, CYP3A4, or any other hepatic isoenzyme studied in vitro for similar GHRH analogs 2. Its interactions are almost entirely pharmacodynamic, meaning they arise from overlapping or opposing physiological effects rather than from competition at metabolic enzymes.

Insulin and Oral Hypoglycemic Agents: The Highest-Risk Category

Growth hormone is a counter-regulatory hormone to insulin. This is not a theoretical concern. GH directly reduces peripheral glucose uptake in skeletal muscle and promotes hepatic gluconeogenesis 3. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency notes that GH replacement "may impair insulin sensitivity" and recommends glucose monitoring in all patients receiving GH therapy 4.

CJC-1295 does not deliver exogenous GH, but it amplifies endogenous GH secretion for days. Patients taking insulin (any formulation), metformin, sulfonylureas, SGLT2 inhibitors, or GLP-1 receptor agonists should expect that CJC-1295 may blunt glycemic control. In a patient on basal insulin, for example, fasting glucose values could drift upward by 10 to 30 mg/dL during the first weeks of CJC-1295 use before a new steady state emerges.

Practical guidance: check fasting glucose and HbA1c at baseline and again at 4 and 12 weeks. Sulfonylurea doses rarely need change, but basal insulin doses may require a 10 to 20% upward titration. GLP-1 agonists (semaglutide, tirzepatide) may partially offset GH-mediated insulin resistance, but this has not been studied in combination with CJC-1295 specifically 5.

Glucocorticoids: Bidirectional Interference

Chronic glucocorticoid use (prednisone ≥5 mg/day equivalent for more than 3 months) suppresses the GH/IGF-1 axis at the hypothalamic and pituitary level 6. Patients on maintenance corticosteroids may experience a blunted response to CJC-1295, requiring higher peptide doses to achieve comparable IGF-1 elevations.

The interaction runs in both directions. GH and IGF-1 increase conversion of cortisone to cortisol by upregulating 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in adipose tissue. A patient on physiologic hydrocortisone replacement for adrenal insufficiency could experience increased cortisol exposure when CJC-1295 raises their GH output, potentially pushing them into a mildly hypercortisolemic state 7.

For patients on replacement-dose hydrocortisone (15 to 25 mg/day), measure morning cortisol and ACTH before and 6 weeks after starting CJC-1295. Dose reduction of hydrocortisone by 2.5 to 5 mg/day may be necessary. Patients using inhaled or topical corticosteroids at standard doses are unlikely to experience clinically significant interaction.

Thyroid Hormones: A Subtle but Measurable Shift

GH enhances peripheral conversion of thyroxine (T4) to triiodothyronine (T3) by increasing type 1 deiodinase activity in the liver 8. In patients with intact thyroid function, this shift is buffered by the hypothalamic-pituitary-thyroid feedback loop. In patients on levothyroxine replacement for hypothyroidism, no such buffer exists.

The result: free T4 may drop while free T3 rises, and TSH may creep upward. A 2009 study of adult GH replacement therapy found that 36% of patients on levothyroxine required a dose increase of 25 to 50 mcg/day after starting GH 8. CJC-1295 produces a less intense but more sustained GH pulse than exogenous GH injection, so the magnitude of thyroid interaction may be smaller but more persistent.

Check TSH and free T4 at 6 and 12 weeks after CJC-1295 initiation in any patient on thyroid replacement. Liothyronine (T3) users may paradoxically experience T3 excess symptoms (tremor, tachycardia, heat intolerance) and should be monitored with free T3 levels rather than TSH alone.

Other GH Secretagogues: Stacking Risks

Combining CJC-1295 with other GH-axis stimulators is common in peptide therapy practice but introduces compounding pharmacodynamic risk. The most frequently stacked compounds include:

CJC-1295 + Ipamorelin. Ipamorelin is a growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor (GHS-R1a), a distinct pathway from the GHRH receptor targeted by CJC-1295. The two peptides produce additive GH release 9. This pairing amplifies every downstream interaction described in this article: greater insulin resistance, stronger thyroid conversion shift, and higher IGF-1 peaks. Monitoring intervals should be shortened to every 4 weeks for the first 3 months.

CJC-1295 + Sermorelin. Both act on the GHRH receptor. Stacking two GHRH agonists offers no proven combination and risks receptor desensitization (tachyphylaxis) within 2 to 4 weeks. This combination should be avoided.

CJC-1295 + MK-677 (ibutamoren). MK-677 is an oral ghrelin mimetic with a 24-hour duration of action. Adding CJC-1295 DAC (8-day half-life) on top of daily MK-677 creates near-continuous GH stimulation. IGF-1 levels can exceed 1.5 times the upper limit of normal, which may carry acromegaly-spectrum side effects (joint pain, edema, carpal tunnel symptoms) and has been linked to theoretical oncologic concern in observational data on acromegaly 10.

Risk-stratification framework for stacking:

| Combination | Mechanism overlap | Risk level | Monitoring frequency | |---|---|---|---| | CJC-1295 + Ipamorelin | Complementary (GHRH + GHRP) | Moderate | Every 4 weeks x 3 months | | CJC-1295 + Sermorelin | Redundant (GHRH + GHRH) | High (tachyphylaxis) | Avoid combination | | CJC-1295 + MK-677 | Complementary (GHRH + ghrelin mimetic) | High (sustained supraphysiologic GH) | Every 4 weeks x 3 months, with IGF-1 cap target | | CJC-1295 + Tesamorelin | Redundant (GHRH + GHRH analog) | High | Avoid combination | | CJC-1295 + GH injection | Exogenous + endogenous amplification | Very high | Contraindicated without endocrinologist oversight |

Anticoagulants and Antiplatelet Agents

No direct pharmacokinetic interaction exists between CJC-1295 and warfarin, direct oral anticoagulants (DOACs), or antiplatelet agents. GH and IGF-1 do modulate plasminogen activator inhibitor-1 (PAI-1) and fibrinogen levels modestly 11. In the GH-deficiency replacement literature, these changes have not translated into clinically significant bleeding or thrombotic events. Patients on warfarin should check INR at baseline and 4 weeks after CJC-1295 initiation as a precaution, but routine anticoagulant dose adjustment is not expected.

Somatostatin Analogs: Direct Pharmacological Antagonism

Octreotide and lanreotide suppress GH secretion by activating somatostatin receptors 2 and 5. These drugs will directly and completely antagonize the effect of CJC-1295. Co-administration is pharmacologically irrational, like pressing the accelerator and brake simultaneously. Patients being treated with somatostatin analogs for acromegaly, neuroendocrine tumors, or refractory diarrhea should not receive CJC-1295 12.

Dopamine Agonists

Cabergoline and bromocriptine suppress prolactin but also modestly suppress GH secretion in some contexts. In normal physiology, dopamine has a paradoxical stimulatory effect on GH in certain hypothalamic circuits. The net effect of combining a dopamine agonist with CJC-1295 is unpredictable and varies by individual. Patients on cabergoline for prolactinoma should have IGF-1 checked at baseline and 8 weeks to determine whether CJC-1295 is producing the expected response 13.

Estrogen and Testosterone: HRT Considerations

Oral estrogen (but not transdermal estradiol) reduces hepatic IGF-1 production through a first-pass effect 14. Women on oral conjugated estrogens or oral estradiol may experience an attenuated IGF-1 response to CJC-1295 compared with women on transdermal estradiol patches or pellets. Switching to transdermal estrogen delivery may improve CJC-1295 efficacy.

Testosterone replacement therapy (TRT) modestly raises IGF-1 levels independently of GH stimulation 15. Men on TRT who add CJC-1295 should expect additive IGF-1 elevation. This is generally well-tolerated, but IGF-1 should be monitored to ensure levels remain below the age-adjusted upper limit of normal.

Monitoring Protocol for Patients on Multiple Interacting Drugs

A practical monitoring timeline for patients starting CJC-1295 alongside interacting medications:

Baseline (before first dose): fasting glucose, HbA1c, IGF-1, GH (random or stimulated), TSH, free T4, free T3, morning cortisol, CBC, comprehensive metabolic panel.

Week 4: fasting glucose, IGF-1. Add INR if on warfarin. Add free T4/TSH if on levothyroxine.

Week 12: full baseline panel repeat. Adjust interacting drug doses based on results. Target IGF-1 within age-adjusted reference range (typically 100 to 300 ng/mL depending on age and sex).

Every 6 months thereafter: IGF-1, fasting glucose, HbA1c, TSH. Annual: comprehensive metabolic panel, lipid panel.

Patients stacking CJC-1295 with ipamorelin or MK-677 should use the Week 4 panel at Weeks 4, 8, and 12 rather than waiting 12 weeks for the second check.

Why No Formal DDI Data Exists

CJC-1295 has never undergone FDA-required drug interaction studies because it has never been submitted for New Drug Application review. The Teichman et al. Phase I study (2006) enrolled healthy young males and excluded subjects on any concomitant medication, meaning even basic safety co-administration data was not collected 1. All interaction guidance therefore comes from extrapolation: the known pharmacodynamics of GH elevation, the published interaction profiles of FDA-approved GH products (somatropin), and clinical experience from compounding pharmacy prescribers.

The FDA's 2003 somatropin class labeling includes drug interaction warnings for glucocorticoids, insulin, oral hypoglycemics, and cytochrome P450-metabolized drugs whose clearance may change with altered body composition during GH therapy 16). These warnings serve as the most relevant analog for CJC-1295 interaction profiling.